BTAI – bioxcel therapeutics, inc. (US:NASDAQ)
Stock Stats
News
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
BioXcel Therapeutics (BTAI) was downgraded by Wall Street Zen from "h
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Form 8-K BioXcel Therapeutics, For: Apr 15
Form 8-K BioXcel Therapeutics, For: Apr 01
Form SCHEDULE 13G/A BioXcel Therapeutics, Filed by: Qatar Investment Authority
Form S-8 BioXcel Therapeutics,
Form 10-K BioXcel Therapeutics, For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.